Dr. Larry Gold, the founder of SomaLogic, was awarded the Lifetime Achievement Award on behalf of the International Society on Aptamers (INSOAP) for his pioneering and extraordinary contributions to the field of aptamers and therapeutics.
Click on the image below to view the investor presentation:
Sign up to receive our news releases
More SomaLogic News
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform
SomaLogic and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction CM Life Sciences II will be renamed and its common stock will be listed on the Nasdaq Global Market under ticker symbol “SLGC.”
SomaLogic, Inc., a global leader in proteomics technology, announced today its intention to broaden its proteomics offerings to pharma, biotechnology and academic research customers by adding smaller protein measurement panel products to its market-leading, large-plex offering.
SomaLogic Inc. today announced the appointment of Jason Cleveland, Ph.D. as the company’s chief technology officer. In this role, Dr. Cleveland will drive technological innovations that will bring the SomaScan® proteomics platform to patients around the world.
SomaLogic Inc. announced today the appointments of Angela Bakker Lee, Ph.D. as executive vice president for healthcare markets, Tracy Hervey, MBA as executive vice president for life sciences markets and David McGovern, MBA as senior vice president of marketing. In these roles, Dr. Bakker Lee, Ms. Hervey and Mr. McGovern will drive business development and marketing efforts for SomaLogic’s proprietary protein measurement technology and growing portfolio of protein-based health information products.
PRESENTATION: The SomaScan® Assay: Biomarker Discovery to Delivery
As part of the Molecular Medicine Tri-Con virtual conference on February 16, 2021, Dr. Sheri Wilcox of SomaLogic described how the SomaScan Assay has been used to identify protein patterns as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.
WEBINAR: Proteomics Reveals the Hidden Impact of Interventions in Diabetes
On January 27, 2021, Dr. Svati Shah (Duke University School of Medicine), Dr. Stephen Williams (SomaLogic) and Dr. Naveed Sattar (University of Glasgow) discussed how proteomic models can be implemented to design more precise treatment strategies for diabetic patients.
PRESENTATION: The SomaScan® Assay and Oncology
As part of the Translational Dx Virtual Summit on September 23, 2020, Dr. Sheri Wilcox, Senior Director, Scientific Liaison and Technical Services, at SomaLogic described the utility of the SomaScan Assay in oncology applications.
WEBINAR: Building a Genetic Atlas of the Human Plasma Proteome
Protein-genotype associations (pQTLs) are an important tool for identifying proteins that link genetic variants with disease states. On August 6, 2020, Dr. Benjamin Sun discussed how he and his colleagues at the University of Cambridge used the SomaScan® Assay to develop a pQTL atlas for the human plasma proteome.
WEBINAR: What Can Proteomics Teach Us About Infectious Disease?
On June 25, 2020, Dr. Kevin Coombs of the University of Manitoba described his work using the SomaScan Assay to identify biological processes associated with infection by Zika virus and various strains of influenza. He also discussed how the SomaScan Assay® could be used to further study infectious disease, including the current COVID-19 pandemic, in the immediate future.
WEBINAR: Plasma Proteins as Comprehensive Indicators of Health
On May 12, 2020, Dr. Stephen Williams (SomaLogic), Dr. Claudia Langenberg (University of Cambridge), and Dr. Peter Ganz (UCSF) discussed their recent proof-of-concept study that illustrated how measuring blood proteins at scale could lead to a future comprehensive “liquid health check.” They also explored the implications of their findings for public health, particularly in the areas of diabetes and cardiovascular disease.
SomaLogic, Inc. announced today that it added $81M to its current funding round with investments from a number of additional investors, for a total Series A raise of $214M. The funds raised in this round will facilitate improving, expanding and commercializing SomaLogic’s world-leading proteomic products in both the clinical and life science markets.
An international consortium led by Medical Research Council researchers in the UK working with SomaLogic performed the largest genetic discovery of host proteins involved in SARS-CoV-2 infection or severe COVID-19. The results are being shared via an open access platform to help investigators around the world prioritize protein targets for new or repurposed drugs to treat COVID-19. The information may also help medical researchers identify patients who are more likely to develop a serious case of COVID-19.
For older news and press releases, please visit our archive.